These results suggested that midostaurin may hinder rituximab-mediated CDC due to the reduced expression of only CD20 in the original BL cells, while the effect of midostaurin on the resistant BL cells requires further examination due to the reduced expression of both CD20 and CD59. This evidence concerns the gene CD59 and Burkitt lymphoma.